Hysen Pharmaceutical announced that company director Dai Ya, deputy general manager Zhang Shengquan, Lou Yanjun, and director Hu Kangkang have reduced their holdings by a total of 102,900 shares through centralized bidding from December 26 to December 31, 2025, accounting for 0.0675% of the total share capital. Among them, Dai Ya, Zhang Shengquan, Lou Yanjun, and Hu Kangkang reduced their holdings by 24420 shares, 25530 shares, 25530 shares, and 24420 shares respectively. Financial Director Pan Aijuan has reduced her holdings by 3,000 shares at an average price of 22.06 yuan/share, and terminated the remaining 21,420 shares reduction plan ahead of schedule.

Hysen Pharmaceutical announced that company director Dai Ya, deputy general manager Zhang Shengquan, Lou Yanjun, and director Hu Kangkang have reduced their holdings by a total of 102,900 shares through centralized bidding from December 26 to December 31, 2025, accounting for 0.0675% of the total share capital. Among them, Dai Ya, Zhang Shengquan, Lou Yanjun, and Hu Kangkang reduced their holdings by 24420 shares, 25530 shares, 25530 shares, and 24420 shares respectively. Financial Director Pan Aijuan has reduced her holdings by 3,000 shares at an average price of 22.06 yuan/share, and terminated the remaining 21,420 shares reduction plan ahead of schedule.